Crinecerfont Patent Expiration

Crinecerfont was first introduced by Neurocrine Biosciences Inc in its drug Crenessity on Dec 13, 2024.

Crinecerfont Patents

Given below is the list of patents protecting Crinecerfont, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in	Drug Patent Number	Drug Patent Title	Drug Patent Expiry	Drug Owner
Crenessity	US12128033	Synthetic methods for preparation of 4-(2-chloro-4-methoxy-5-methylphenyl)-n-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-n-prop-2-ynyl-1,3-thiazol-2-amine	Jun 09, 2041	Neurocrine
Crenessity	US10905690	Treatment of congenital adrenal hyperplasia	Jan 21, 2035	Neurocrine
Crenessity	US11311544	Treatment of congenital adrenal hyperplasia	Jan 21, 2035	Neurocrine
Crenessity	US11730739	Treatment of congenital adrenal hyperplasia	Jan 21, 2035	Neurocrine

Drugs Generating Over $1 Billion in Annual Revenue

Explore the top-performing drugs that dominate the pharmaceutical industry

View List

NCE-1 Patent Expiry in the Next 1 Year

Identify opportunities as new chemical entity (NCE-1) patents approach expiry

View List

Recently Granted Patents in EP

Find the opportunity to file Oppositions

View List